165 related articles for article (PubMed ID: 33632246)
1. Hypofibrinogenemia is associated with a high degree of risk in infectious diseases: a post-hoc analysis of post-marketing surveillance of patients with disseminated intravascular coagulation treated with thrombomodulin alfa.
Kawasugi K; Wada H; Honda G; Kawano N; Uchiyama T; Madoiwa S; Takezako N; Suzuki K; Seki Y; Ikezoe T; Iba T; Okamoto K
Thromb J; 2021 Feb; 19(1):12. PubMed ID: 33632246
[TBL] [Abstract][Full Text] [Related]
2. Post-marketing surveillance data of thrombomodulin alfa: sub-analysis in patients with sepsis-induced disseminated intravascular coagulation.
Eguchi Y; Gando S; Ishikura H; Saitoh D; Mimuro J; Takahashi H; Kitajima I; Tsuji H; Matsushita T; Tsujita R; Nagao O; Sakata Y
J Intensive Care; 2014; 2(1):30. PubMed ID: 25520842
[TBL] [Abstract][Full Text] [Related]
3. Post-marketing surveillance of thrombomodulin alfa, a novel treatment of disseminated intravascular coagulation - safety and efficacy in 1,032 patients with hematologic malignancy.
Asakura H; Takahashi H; Tsuji H; Matsushita T; Ninomiya H; Honda G; Mimuro J; Eguchi Y; Kitajima I; Sakata Y
Thromb Res; 2014 Mar; 133(3):364-70. PubMed ID: 24440141
[TBL] [Abstract][Full Text] [Related]
4. Analysis of the association between resolution of disseminated intravascular coagulation (DIC) and treatment outcomes in post-marketing surveillance of thrombomodulin alpha for DIC with infectious disease and with hematological malignancy by organ failure.
Kawano N; Wada H; Uchiyama T; Kawasugi K; Madoiwa S; Takezako N; Suzuki K; Seki Y; Ikezoe T; Hattori T; Okamoto K
Thromb J; 2020; 18():2. PubMed ID: 32047363
[TBL] [Abstract][Full Text] [Related]
5. Impact of recombinant soluble thrombomodulin (thrombomodulin alfa) on disseminated intravascular coagulation.
Mimuro J; Takahashi H; Kitajima I; Tsuji H; Eguchi Y; Matsushita T; Kuroda T; Sakata Y
Thromb Res; 2013 May; 131(5):436-43. PubMed ID: 23566534
[TBL] [Abstract][Full Text] [Related]
6. Effects of recombinant human soluble thrombomodulin treatment for disseminated intravascular coagulation at a single institution--an analysis of 62 cases caused by infectious diseases and 30 cases caused by hematological diseases.
Kawano N; Tasaki A; Kuriyama T; Tahara Y; Yoshida S; Ono N; Himeji D; Yamashita K; Shibata Y; Goto T; Inoue T; Yokota-Ikeda N; Uezono S; Yuge A; Nishiguchi T; Kinjo T; Ogura Y; Beppu K; Ueda Y; Kinoshita M; Moritake H; Shimoda K; Ochiai H; Ueda A
Intern Med; 2014; 53(3):205-13. PubMed ID: 24492688
[TBL] [Abstract][Full Text] [Related]
7. Thrombomodulin alfa in the treatment of infectious patients complicated by disseminated intravascular coagulation: subanalysis from the phase 3 trial.
Aikawa N; Shimazaki S; Yamamoto Y; Saito H; Maruyama I; Ohno R; Hirayama A; Aoki Y; Aoki N
Shock; 2011 Apr; 35(4):349-54. PubMed ID: 21068698
[TBL] [Abstract][Full Text] [Related]
8. Recombinant human soluble thrombomodulin (thrombomodulin alfa) to treat disseminated intravascular coagulation in solid tumors: results of a one-arm prospective trial.
Tamura K; Saito H; Asakura H; Okamoto K; Tagawa J; Hayakawa T; Aoki N
Int J Clin Oncol; 2015 Aug; 20(4):821-8. PubMed ID: 25385713
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors in patients with septic disseminated intravascular coagulation treated with thrombomodulin: the effect of reduced thrombomodulin dose; a single-center, retrospective, observational study.
Nishita Y; Taga M; Sakurai M; Iinuma Y; Masauji T
J Pharm Health Care Sci; 2022 Dec; 8(1):32. PubMed ID: 36503588
[TBL] [Abstract][Full Text] [Related]
10. Recombinant soluble human thrombomodulin (thrombomodulin alfa) in the treatment of neonatal disseminated intravascular coagulation.
Shirahata A; Mimuro J; Takahashi H; Kitajima I; Tsuji H; Eguchi Y; Matsushita T; Kajiki M; Honda G; Sakata Y
Eur J Pediatr; 2014 Mar; 173(3):303-11. PubMed ID: 24005342
[TBL] [Abstract][Full Text] [Related]
11. Surveillance of the safety and efficacy of recombinant human soluble thrombomodulin in patients with obstetrical disseminated intravascular coagulation.
Kobayashi T; Kajiki M; Nihashi K; Honda G
Thromb Res; 2017 Nov; 159():109-115. PubMed ID: 29153952
[TBL] [Abstract][Full Text] [Related]
12. Clinical features and outcomes of 35 disseminated intravascular coagulation cases treated with recombinant human soluble thrombomodulin at a single institution.
Kawano N; Yoshida S; Ono N; Himeji D; Nagahiro Y; Sayaka Kawano ; Yamashita K; Ikeda N; Uezono S; Ochiai H; Kawano F; Kikuchi I; Ishikawa F; Shimoda K; Ueda A; Akashi K
J Clin Exp Hematop; 2011; 51(2):101-7. PubMed ID: 22104308
[TBL] [Abstract][Full Text] [Related]
13. Clinical Features of Disseminated Intravascular Coagulation According to the French-American-British Classification in Patients With Acute Leukemia and Thrombomodulin Alfa Treatment-A Cohort Study Using a Postmarketing Surveillance Database.
Yoshinobu S; Honda G; Kawano N; Uchiyama T; Kawasugi K; Madoiwa S; Takezako N; Takayuki I; Wada H
Clin Appl Thromb Hemost; 2021; 27():10760296211054094. PubMed ID: 34870471
[TBL] [Abstract][Full Text] [Related]
14. Severe Antithrombin Deficiency May be Associated With a High Risk of Pathological Progression of DIC With Suppressed Fibrinolysis.
Wada H; Honda G; Kawano N; Uchiyama T; Kawasugi K; Madoiwa S; Takezako N; Suzuki K; Seki Y; Ikezoe T; Iba T; Okamoto K
Clin Appl Thromb Hemost; 2020; 26():1076029620941112. PubMed ID: 32833540
[TBL] [Abstract][Full Text] [Related]
15. Thrombomodulin alfa treatment in patients with acute promyelocytic leukemia and disseminated intravascular coagulation: a retrospective analysis of an open-label, multicenter, post-marketing surveillance study cohort.
Matsushita T; Watanabe J; Honda G; Mimuro J; Takahashi H; Tsuji H; Eguchi Y; Kitajima I; Sakata Y
Thromb Res; 2014 May; 133(5):772-81. PubMed ID: 24636871
[TBL] [Abstract][Full Text] [Related]
16. Usefulness of the APTT waveform for the diagnosis of DIC and prediction of the outcome or bleeding risk.
Suzuki K; Wada H; Matsumoto T; Ikejiri M; Ohishi K; Yamashita Y; Imai H; Iba T; Katayama N
Thromb J; 2019; 17():12. PubMed ID: 31297038
[TBL] [Abstract][Full Text] [Related]
17. Sepsis-Associated DIC with Decreased Levels of Antithrombin and Fibrinogen is the Target for Combination Therapy with Thrombomodulin Alfa and Antithrombin.
Wada H; Kawasugi K; Honda G; Kawano N; Uchiyama T; Madoiwa S; Takezako N; Suzuki K; Seki Y; Ikezoe T; Iba T; Okamoto K
TH Open; 2023 Jan; 7(1):e65-e75. PubMed ID: 36846833
[No Abstract] [Full Text] [Related]
18. Effect of Thrombomodulin Alfa on Disseminated Intravascular Coagulation in Patients with Lung Cancer.
Nakano K; Sugiyama K; Satoh H; Arifuku H; Fujimatsu T; Yoshida N; Watanabe H; Tokita S; Wakayama T; Tatewaki M; Souma R; Masuda H; Koyama K; Hirata H; Fukushima Y
Intern Med; 2017; 56(14):1799-1806. PubMed ID: 28717074
[TBL] [Abstract][Full Text] [Related]
19. Early thrombomodulin-α administration outcome for acute disseminated intravascular coagulopathy in gastrointestinal surgery.
Konishi H; Okamoto K; Shoda K; Arita T; Kosuga T; Morimura R; Komatsu S; Murayama Y; Shiozaki A; Kuriu Y; Ikoma H; Nakanishi M; Ichikawa D; Fujiwara H; Otsuji E
World J Gastroenterol; 2017 Feb; 23(5):891-898. PubMed ID: 28223734
[TBL] [Abstract][Full Text] [Related]
20. Multicenter clinical experience with recombinant soluble thrombomodulin for disseminated intravascular coagulation associated with severe acute cholecystitis.
Ogura T; Eguchi T; Amano M; Sano T; Nishioka N; Miyano A; Tsujimae M; Tanimura H; Yamada T; Terashima Y; Okada A; Higuchi K
Thromb Res; 2019 Apr; 176():74-78. PubMed ID: 30780007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
